Lean body mass, Interleukin 18, and metabolic syndrome in apparently healthy Chinese

PLoS ONE

Volumn 6, Issue 3, 2011, Pages

  Sun, Liang ^a   Hu, Frank B ^b   Yu, Zhijie ^a   Li, Huaixing ^a   Liu, Huaiyu ^c   Wang, Xiangdong ^c   Yu, Danxia ^a   Wu, Hongyu ^a   Zhang, Geng ^a   Zong, Geng ^a   Liu, Yong ^a   Lin, Xu ^a  

^a Shanghai Jiao Tong University Affiliated Sixth People s Hospital   (China)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c Shanghai Center for Disease Control and Prevention   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INTERLEUKIN 18; INTERLEUKIN 6; LIPOPOLYSACCHARIDE BINDING PROTEIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; ASIAN AMERICAN; BLOOD PRESSURE; BODY COMPOSITION; BODY MASS; CHINESE; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; LEAN BODY WEIGHT; MALE; METABOLIC SYNDROME X; MOLECULAR WEIGHT; POPULATION BASED CASE CONTROL STUDY; PROTEIN BLOOD LEVEL; WAIST CIRCUMFERENCE; ASIAN; BLOOD; BODY WEIGHT; CHINA; CONFIDENCE INTERVAL; HEALTH; MIDDLE AGED; NONPARAMETRIC TEST; PATHOPHYSIOLOGY; PHYSIOLOGY; RISK;

ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; BODY COMPOSITION; BODY WEIGHT; CHINA; CONFIDENCE INTERVALS; FEMALE; HEALTH; HUMANS; INTERLEUKIN-18; MALE; METABOLIC SYNDROME X; MIDDLE AGED; ODDS RATIO; STATISTICS, NONPARAMETRIC; THINNESS;

EID: 79952792330     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0018104     Document Type: Article

References (30)

1. Dandona P, Aljada A, Bandyopadhyay A, (2004) Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol 25: 4-7.
2. Kahn SE, Hull RL, Utzschneider KM, (2006) Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 444: 840-846.
3. Skurk T, Kolb H, Muller-Scholze S, Rohrig K, Hauner H, et al. (2005) The proatherogenic cytokine interleukin-18 is secreted by human adipocytes. Eur J Endocrinol 152: 863-868.
4. Dinarello CA, (2006) Interleukin 1 and interleukin 18 as mediators of inflammation and the aging process. Am J Clin Nutr 83: 447S-455S.
5. Okamura H, Tsutsui H, Kashiwamura S, Yoshimoto T, Nakanishi K, (1998) Interleukin-18: a novel cytokine that augments both innate and acquired immunity. Adv Immunol 70: 281-312.
6. Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H, (2001) Interleukin-18 is a unique cytokine that stimulates both Th1 and Th2 responses depending on its cytokine milieu. Cytokine Growth Factor Rev 12: 53-72.
7. Gracie JA, Robertson SE, McInnes IB, (2003) Interleukin-18. J Leukoc Biol 73: 213-224.
8. Blankenberg S, Tiret L, Bickel C, Peetz D, Cambien F, et al. (2002) Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina. Circulation 106: 24-30.
9. Blankenberg S, Luc G, Ducimetiere P, Arveiler D, Ferrieres J, et al. (2003) Interleukin-18 and the risk of coronary heart disease in European men- The Prospective Epidemiological Study of Myocardial Infarction (PRIME). Circulation 108: 2453-2459.
10. Bosch M, Lopez-Bermejo A, Vendrell J, Musri M, Ricart W, et al. (2005) Circulating IL-18 concentration is associated with insulin sensitivity and glucose tolerance through increased fat-free mass. Diabetologia 48: 1841-1843.
11. Hung J, McQuillan BM, Chapman CM, Thompson PL, Beilby JP, (2005) Elevated interleukin-18 levels are associated with the metabolic syndrome independent of obesity and insulin resistance. Arterioscler Thromb Vasc Biol 25: 1268-1273.
12. Thorand B, Kolb H, Baumert J, Koenig W, Chambless L, et al. (2005) Elevated levels of interleukin-18 predict the development of type 2 diabetes: results from the MONICA/KORA Augsburg Study, 1984-2002. Diabetes 54: 2932-2938.
13. Hivert MF, Sun Q, Shrader P, Mantzoros CS, Meigs JB, et al. (2009) Circulating IL-18 and the risk of type 2 diabetes in women. Diabetologia 52: 2101-2108.
14. Yoon KH, Lee JH, Kim JW, Cho JH, Choi YH, et al. (2006) Epidemic obesity and type 2 diabetes in Asia. Lancet 368: 1681-1688.
15. Evans J, Collins M, Jennings C, van der Merwe L, Soderstrom I, et al. (2007) The association of interleukin-18 genotype and serum levels with metabolic risk factors for cardiovascular disease. Eur J Endocrinol 157: 633-640.
16. Zirlik A, Abdullah SM, Gerdes N, MacFarlane L, Schonbeck U, et al. (2007) Interleukin-18, the metabolic syndrome, and subclinical atherosclerosis: results from the Dallas Heart Study. Arterioscler Thromb Vasc Biol 27: 2043-2049.
17. Herder C, Baumert J, Kolb H, Koenig W, Martin S, et al. (2006) Circulating levels of interleukin-18 independent of body fat and fat-free mass: results from the MONICA/KORA study. Diabetes Care 29: 174-175.
18. Esposito K, Pontillo A, Ciotola M, Di Palo C, Grella E, et al. (2002) Weight loss reduces interleukin-18 levels in obese women. J Clin Endocrinol Metab 87: 3864-3866.
19. Esposito K, Pontillo A, Di Palo C, Giugliano G, Masella M, et al. (2003) Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA 289: 1799-1804.
20. Krogh-Madsen R, Plomgaard P, Moller K, Mittendorfer B, Pedersen BK, (2006) Influence of TNF-alpha and IL-6 infusions on insulin sensitivity and expression of IL-18 in humans. Am J Physiol Endocrinol Metab 291: E108-E114.
21. Sun L, Yu Z, Ye X, Zou S, Li H, et al. (2010) A marker of endotoxemia is associated with obesity and related metabolic disorders in apparently healthy Chinese. Diabetes Care 33: 1925-1932.
22. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, et al. (2005) Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement: Executive Summary. Circulation 112: E285-E290.
23. Wang J, Rennie KL, Gu W, Li H, Yu Z, et al. (2009) Independent associations of body-size adjusted fat mass and fat-free mass with the metabolic syndrome in Chinese. Ann Hum Biol 36: 110-121.
24. Wells JC, (2001) A critique of the expression of paediatric body composition data. Arch Dis Child 85: 67-72.
25. Fain JN, Tichansky DS, Madan AK, (2006) Most of the interleukin 1 receptor antagonist, cathepsin S, macrophage migration inhibitory factor, nerve growth factor, and interleukin 18 release by explants of human adipose tissue is by the non-fat cells, not by the adipocytes. Metabolism 55: 1113-1121.
26. You T, Ryan AS, Nicklas BJ, (2004) The metabolic syndrome in obese postmenopausal women: relationship to body composition, visceral fat, and inflammation. J Clin Endocrinol Metab 89: 5517-5522.
27. Nistala R, Stump CS, (2006) Skeletal muscle insulin resistance is fundamental to the cardiometabolic syndrome. J Cardiometab Syndr 1: 47-52.
28. Petersen KF, Dufour S, Savage DB, Bilz S, Solomon G, et al. (2007) The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome. Proc Natl Acad Sci U S A 104: 12587-12594.
29. Kojima H, Aizawa Y, Yanai Y, Nagaoka K, Takeuchi M, et al. (1999) An essential role for NF-kappa B in IL-18-induced IFN-gamma expression in KG-1 cells. J Immunol 162: 5063-5069.
30. Lepper PM, Schumann C, Triantafilou K, Rasche FM, Schuster T, et al. (2007) Association of lipopolysaccharide-binding protein and coronary artery disease in men. J Am Coll Cardiol 50: 25-31.